Physician profile
Aaron E Lisberg
NPI 1043509797
$173,534.41
in general payments reported to CMS, 2019-2025
20 companies · $60K in 2025
The $60K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $1,193 · 2021: $15K · 2022: $19K · 2023: $30K · 2024: $21K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $74K · Travel and Lodging: $25K · Honoraria: $10K · Food and Beverage: $1,208 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,083 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $74,074.60 |
| Travel and Lodging | $24,892.23 |
| Honoraria | $10,150.00 |
| Food and Beverage | $1,208.45 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,082.86 |
| Education | $139.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $49,015.09 | 2019-2025 | Datroway, Tagrisso |
| Biontech Se | $19,749.42 | 2025 | |
| Daiichi Sankyo INC. | $18,050.81 | 2023-2025 | Datroway |
| Novocure INC. | $16,981.63 | 2019-2023 | |
| Aadi Bioscience, INC. | $10,800.00 | 2025 | Fyarro |
| Eli Lilly and Company | $9,800.00 | 2021-2022 | |
| Abbvie INC. | $9,738.94 | 2024-2025 | |
| Pfizer INC. | $7,136.23 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $7,080.47 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $5,895.00 | 2022-2023 | Libtayo |
| Janssen Biotech, INC. | $4,680.00 | 2023 | Rybrevant |
| Genzyme Corporation | $2,996.00 | 2022 | |
| G1 Therapeutics, INC. | $2,936.95 | 2023 | Cosela |
| Novartis Pharmaceuticals Corporation | $2,080.87 | 2020-2023 | |
| Janssen Scientific Affairs, LLC | $2,030.00 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,520.00 | 2024-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $1,468.00 | 2023 | |
| Astrazeneca Uk Limited | $1,025.00 | 2025 | Datroway |
| Jazz Pharmaceuticals INC. | $550.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Lisberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.